Glycine — Research Evidence
The summary below was generated by an AI system (Claude) based on the studies listed. It is a synthesis tool, not a clinical opinion. Read individual studies for full context.
Glycine is a non-essential (and conditionally essential) amino acid that serves several distinct physiological roles: it is an inhibitory neurotransmitter in the spinal cord and brainstem, acting on strychnine-sensitive glycine receptors; it is one of three precursors for glutathione (the body's principal endogenous antioxidant); it is the most abundant amino acid in collagen; and it is required for creatine synthesis. The breadth of these roles has generated interest across sleep, longevity, metabolic, and musculoskeletal research.
The most developed area of human evidence concerns sleep quality. Bannai and Kawai (2012) summarized human pilot data showing that 3 g of glycine taken before sleep improved subjective sleep quality and reduced daytime fatigue. A distinctive proposed mechanism — reduction in core body temperature via peripheral vasodilation — distinguishes glycine from sedative sleep aids and is biologically plausible given what is known about thermoregulatory sleep initiation. However, the clinical trials in this literature are small (n ≈ 11), and the field lacks large, registered, pre-specified RCTs with polysomnographic endpoints in well-characterized populations.
A growing body of work on the glycine + N-acetylcysteine (GlyNAC) combination is notable. Kumar et al. (2017, expanded in subsequent work by Sekhar's group) found that GlyNAC supplementation over 24 weeks in older adults corrected glutathione deficiency, reduced markers of oxidative stress and mitochondrial dysfunction, and improved physical function across several hallmarks-of-aging endpoints. These findings are mechanistically compelling and clinically interesting, but the samples remain small and the evidence is early-stage. Importantly, the GlyNAC studies do not isolate glycine's individual contribution from NAC's.
A modeling analysis (Meléndez-Hevia et al., 2013) argued that glycine demand from collagen turnover and metabolic pathways substantially exceeds what endogenous synthesis and typical protein intake can supply — a "hidden" dietary gap attributable to the decline of collagen-rich foods (bone broth, skin, connective tissue) in modern diets. This hypothesis is thought-provoking and increasingly cited in the popular health space, but it rests on metabolic modeling rather than clinical intervention data.
Overall, glycine has a favorable safety record — no established Tolerable Upper Intake Level (UL), and doses of 15–60 g/day have been studied (for schizophrenia) without serious adverse events. The sleep evidence is suggestive and mechanistically grounded but not yet robust. The glutathione/longevity evidence is early but directionally consistent. Individuals interested in glycine for sleep or antioxidant support may consider it a low-risk, evidence-informed option while acknowledging that the clinical evidence base is still maturing.
Key findings
- ✓Glycine (3 g before sleep) improved subjective sleep quality and reduced daytime fatigue in small human trials; proposed mechanism involves lowering core body temperature.
- ✓GlyNAC (glycine + NAC) supplementation corrected glutathione deficiency and improved multiple aging biomarkers in older adults in a small RCT.
- ✓Metabolic modeling suggests modern diets may undersupply glycine relative to demand, given low collagen food consumption.
- ✓Glycine has an unusually clean safety record; no established Tolerable Upper Intake Level; high doses studied in schizophrenia without serious harm.
- ✓Glycine is a structural precursor to collagen, glutathione, and creatine — roles relevant to joint, antioxidant, and energy metabolism research.
Evidence gaps
- ?Large, well-powered, pre-registered RCTs on sleep outcomes are lacking.
- ?GlyNAC research cannot currently isolate glycine's individual contribution from NAC's contribution.
- ?The dietary gap hypothesis (glycine insufficiency) is based on metabolic modeling, not clinical intervention data.
- ?Long-term supplementation effects beyond 6 months are understudied.
- ?Evidence in younger, healthy adults is sparse across most outcome domains.
Safety summary
Glycine has one of the most favorable safety profiles of any amino acid supplement. No Tolerable Upper Intake Level (UL) has been established. Doses up to 60 g/day have been studied in schizophrenia research without serious adverse events. The most commonly reported effect at supplemental doses (3–10 g) is mild GI discomfort in some individuals. A known interaction exists with clozapine (an antipsychotic) — glycine may blunt clozapine efficacy; individuals on antipsychotic medications should consult their prescriber before using glycine supplements.
Studies (3)
New therapeutic strategy for amino acid medicine: glycine improves the quality of sleep
Glycine supplementation (3 g before sleep) improved subjective sleep quality, reduced daytime fatigue, and was associated with a lowering of core body temperature — a proposed mechanism for its sleep-promoting effect.
May improve subjective sleep quality and reduce fatigue through thermoregulatory mechanisms
No adverse events reported at 3 g doses; glycine is generally well tolerated
Small sample; short trial duration; largely mechanistic review with limited powered RCT data
Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, physical function, and aging hallmarks
GlyNAC (glycine + N-acetylcysteine) supplementation in older adults corrected glutathione deficiency, reduced oxidative stress, improved mitochondrial dysfunction, and improved multiple aging hallmarks over 24 weeks.
Glycine combined with NAC may support glutathione synthesis and improve markers of biological aging in older adults
Well-tolerated; no serious adverse events reported
Small sample size; combination supplement (cannot isolate glycine effect alone); older adult population only
Nitrogen balance and aminoaciduria after glycine loading: potential for simple assessment of dietary protein status
The metabolic demand for glycine substantially exceeds what can be synthesized endogenously or obtained from typical dietary protein, suggesting a conditional deficiency of glycine is common in modern diets — particularly those low in collagen-rich foods.
Modern diets may be insufficient in glycine relative to metabolic demand, supporting consideration of supplementation
No direct safety concerns raised; observational analysis only
Modeling/observational study; does not directly test supplementation outcomes in humans